FLT3-ITD occurs in 20.4% of adult AML patients [11], who are classified as intermediate-risk cases in the absence of adverse-risk genetic lesions, according to the European LeukemiaNet 2022 classification [12]. Here, FLT3 is linked to acute myeloid leukemia.